These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35155258)

  • 1. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Suárez GM; Catalá M; Peña Y; Portela S; Añé-Kourí AL; González A; Lorenzo-Luaces P; Díaz M; Molina MLA; Pereira K; Hernández JC; Ramos R; Reyes MC; Ledón N; Mazorra Z; Crombet T; Lage A; Saavedra D
    Front Oncol; 2022; 12():823287. PubMed ID: 35155258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly.
    Saavedra D; Fuertes SA; Suárez GM; González A; Lorenzo-Luaces P; García B; Aznar E; Mazorra Z; Crombet T; Speiser DE; Lage A
    Exp Gerontol; 2019 Sep; 124():110633. PubMed ID: 31207285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
    Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
    Front Oncol; 2022; 12():958043. PubMed ID: 35992783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
    Saavedra D; Crombet T
    Front Immunol; 2017; 8():269. PubMed ID: 28348561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
    Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
    Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.
    Suárez GM; Añé-Kourí AL; González A; Lorenzo-Luaces P; Neninger E; Salomón EE; Cordero L; Catalá M; Ledón N; Pereira K; Sánchez MG; García B; Crombet T; Mazorra Z; Saavedra D; Lage A
    Cancer Immunol Immunother; 2021 Jun; 70(6):1735-1743. PubMed ID: 33388995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.
    Saavedra D; García B; Lorenzo-Luaces P; González A; Popa X; Fuentes KP; Mazorra Z; Crombet T; Neninger E; Lage A
    Cancer Immunol Immunother; 2016 Jan; 65(1):37-45. PubMed ID: 26589409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
    Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
    J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
    [No Abstract]   [Full Text] [Related]  

  • 9. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
    Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
    BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
    Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
    Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
    Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
    Front Oncol; 2021; 11():639745. PubMed ID: 34211836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
    Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
    J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.